CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26–29 March 2014 by Beekman, Jeffrey M. et al.
www.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 13 (2014) 363–372CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy:
Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta,
26–29 March 20141. OverviewCystic fibrosis (CF) is a life-shortening genetic disease
caused by loss-of-function mutations of the Cystic Fibrosis
Transmembrane conductance Regulator (CFTR) gene that
encodes an anion channel critical for epithelial ion and fluid
transport [1]. Almost 2000 gene mutations have been described
in CFTR, which can be grouped according to their disruptive
mechanism on CFTR function, and association with residual
function and disease severity [2] (www.genet.sickkids.on.ca
and www.cftr2.org). These mutations range from no functional
protein expression (class I), severely impaired folding and
trafficking (class II), gating (class III), conductance (IV), to
limited apical expression of normal functioning CFTR (class V)
associated with significant residual function [3]. A sixth class
associated with functional but unstable plasma membrane
expression of CFTR that associates with severe disease has also
been proposed [3].
Recent FDA/EMEA approval of the first CFTR modulator
drug (ivacaftor) for clinical use in patients with the G551D
gating mutation and more recent FDA approval for another 8
class III mutations provided strong proof-of-concept that
pharmacological manipulation of CFTR protein synthesis
and/or function can bring clear clinical benefit to CF patients,
albeit only for 4–5% of all CF patients. This opened new
opportunities to apply the same approach to develop the
so-called “CFTR protein enhancing drugs" for additional
CFTR mutations, and so as to extend the applicability of
CFTR-targeting pharmacotherapy to more CF patients.
Nevertheless, the nearly 2000 mutations so far reported in the
CFTR gene make this a colossal endeavor.
Therefore, CF Patients Associations foster approaches to
speed up the process of bringing CFTR modulator therapies
(including ivacaftor) to a greater number of patients. CFTR
dysfunction as the basis to stratified or precision or even
personalized medicine to treat CF was thus the proposed topic
of this seminar which was organized by the Patients'
Associations from the Netherlands, Germany, and France in
collaboration with ECFS as a pre-conference meeting to thehttp://dx.doi.org/10.1016/j.jcf.2014.05.00711th ECFS Basic Science Conference that took place in Malta,
26–29 March 2014.
Its purpose was to have key experts in the field reviewing
and discussing how innovative approaches, including the ex
vivo use of tissue samples from patients (rectal biopsies,
intestinal organoids, cells from nasal scrapings or epithelial
cells differentiated from patient-specific induced pluripotent
stem (iPS) cells) can be validated for better and more accurate
diagnosis, prognosis as well as in preclinical research to
determine individual patients responsiveness to CFTR correc-
tors and potentiators directly on his/her tissues (personalized
medicine). Finally, it was also discussed how these approaches
can be explored to expand drug discovery of new compounds
using primary tissues for high-throughput approaches or as
secondary screening models.
For the generalized usage of these innovative approaches as
surrogate markers in clinical trials or in personalized medicine,
however, the CF community has to move towards more
standardized and accessible formats.
The possibilities arising from basic research are constantly
evolving and major breakthroughs in other apparently unrelated
areas (e.g. adult stem cell cultures such as intestinal organoids
or induced pluripotent progenitor stem cell derivatives) help
moving the field forward rapidly. Thus, as a community we
should not “write things on stone”, but instead we need to be
alert and open to test, validate and introduce new approaches
which can be advantageous to CF patients in many respects,
namely to increase the sensitivity, specificity and speed of CF
diagnosis and also to identify responders to therapies. Our goal
should be to diagnose and to treat 100% of CF patients, which
is certainly not the case at present.1.1. General overview of CFTR biomarkers by Isabelle
Sermet-Gaudelus
The meeting started with an overview by Isabelle
Sermet-Gaudelus describing how different existing in vivo
bioassays have the potential to become a surrogate outcome for
clinical trials of CFTR modulators [4]. It was highlighted that
Table 1
Comparison of the characteristics of different CFTR biomarkers in clinical use.
CFTR biomarker Nasal transepithelial potential Sweat Cl− test Rectal transepithelial Cl− secretion
Target Reflects CFTR function in the respiratory
tract, the organ strongly related to
CF survival
Reflects CFTR function in an organ
unaffected by chronic infection and
inflammation
Reflects CFTR function in an organ usually
affected by the disease
Reproducibility/
reliability
Not extensively assessed Not extensively assessed Not extensively assessed
Validation Some correlation with respiratory clinical
endpoints
Discriminates between healthy and
typical CF but more challenging in
CF-PS patients and CFTR-related
diseases
Some correlation with clinical
phenotype (exploratory studies)
Responsiveness Seems sensitive to changes in CFTR
activity, but needs further confirmation
Seems sensitive to small changes in
CFTR activity
Ability to detect very low amount of active
CFTR in a tissue with exceptionally high
turnover (exploratory studies)
Type of study Phase-II trials Phase-II and -III trials Phase-II trials
Feasibility to test novel CFTR therapeutics
ex vivo
Limitations Unreliable in subjects with acute upper
respiratory tract infection, extensive nasal
polyps or after prior sinus surgery
Potentially modified by CF-related
inflammation, which decreases its
specificity and sensitivity
Threshold of response not defined
Does not correlate to respiratory
improvements
Threshold of response not defined
Threshold of response not defined
Feasibility and
availability
Requires highly trained staff, available in
few centers
Wide Very low numbers of centers and short
viability of rectal biopsies
Some patients may be reluctant for rectal
biopsy
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measurements deriving from these bioassays with changes in
clinical outcomes in the same patients (Table 1). This heralds a
new era in CF care where therapeutic choices may be driven by
patient specific biomarker responses to a bioactive compound,
thus providing rationale for a personalized medicine strategy
tailored for every CF patient in the very near future.
Sermet-Gaudelus briefly described three CFTR bioassays,
which so far have been carried out in three epithelia: sweat
gland, airway epithelium and intestine. Below is a summary of
the presentation.
1.1.1. Respiratory epithelium and transnasal epithelium
chloride (Cl−) secretion
The respiratory transepithelial potential difference (PD) is by
far the most extensively validated biomarker. This functional
examination allows to measure in vivo voltage potential
resulting from transepithelial ion fluxes at the mucosal surface,
and has mostly focussed on the nasal mucosa [4]. Nasal PD
(NPD) has been successfully used to measure CFTR modulator
therapy in G551D patients with the potentiator ivacaftor [5]. In
this phase 2 study NPD responded to ivacaftor in a dose-
dependent fashion to treatment, similarly as was observed for
airway cultures. Most importantly, improvements in CFTR
ion-channel function in the nasal mucosa were also related to
improvements in lung function [6]. These data demonstrate that
NPD clearly reflects physiology of the native respiratory tissue
and correlates to clinical status, consistent with the fact that this
biomarker might predict clinical outcome and can be used as a
valuable outcome parameter for future clinical trials.1.1.2. Sweat gland and sweat Cl− concentration
Sweat Cl− concentration is responsive to CFTR functional
rescue, as shown in the phase 2 ivacaftor dose-escalation
studies [5]. This responsiveness seems however larger than
change in nasal transepithelial Cl− transport suggesting higher
sensitivity of the sweat Cl− biomarker to CFTR altering
treatment. Indeed, ivacaftor induced a mean change in sweat
Cl− of about 40–50 mEq/L, which establishes a “current” in
vivo benchmark for CFTR modifier responses [5,6], and
reduced sweat Cl− levels to levels lower than the diagnostic
threshold of the typical CF (60 mEq/L). New sweat gland
biomarkers (see below) that have discriminative power at
higher levels of CFTR function (e.g. between pancreatic
sufficient CF and healthy controls) may be useful for a clear
diagnosis in these treated individuals and as an adjunctive
outcome measure of treatment.
The current sweat Cl− measurement is not a perfect surrogate
endpoint for CF lung disease, as shown by the limited correlation
of its change with improvement in FEV1 in phase 3 studies both
with single-drug ivacaftor and combination ivacaftor/lumacaftor
in F508del homozygote patients [6,7]. This may be explained by
the fact that FEV1 reflects a heterogeneous expression of CFTR
in the lung, which is modified by many factors including
the environment, whereas sweat Cl− is reflective only of the
absorptive activity of CFTR activity in the sweat duct.
1.1.3. Intestinal epithelium and trans-rectal epithelium
Cl− secretion
CFTR is the dominant, if not sole, apical Cl− channel in
the intestine. Intestinal current measurements on ex vivo
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20% of wild type-CFTR protein is already sufficient to
normalize transepithelial anion secretion indicating the high
sensitivity of this biomarker. Small gain in CFTR expression
or function induced by CFTR modulator compounds (e.g., 1–
5% of wild-type values) will thus result in a large gain in
intestinal Cl− transport, e.g., from 5 to 25% of wild-type
controls (Hugo de Jonge, personal data). Importantly, the
aggregate response to multiple secretagogues (carbachol and
forskolin) of rectal transepithelial Cl− transport correlates
with Cl− in sweat. Moreover, it discriminates between
pancreatic insufficient CF patients and healthy subjects and
is related to pancreatic function and FEV1 [8–10].
This test is very useful when NPD measurements may be
impossible, for example because of acute upper respiratory tract
infection, extensive nasal polyps or after prior sinus surgery or
when infants are too small to allow performing NPD.
Moreover, it is done on native epithelium, in a tissue with
exceptionally high cell turnover, suggesting that the effect of
correction might be seen very early and importantly, it is the
only biomarker that can directly assess the beneficial effects of
pure CFTR correctors or potentiators ex vivo. However, the
difficulty of this test is its current limited availability and the
impossibility of centralized laboratory because of the short
viability of rectal tissue, thus still precluding its widespread use.
1.1.4. CFTR biomarkers: current challenges and
future prospects
Before using CFTR biomarkers as a surrogate outcome
measure in clinical trials, several issues have to be resolved.
Data are needed on repeatability (intra- and inter-assay
variation in the same individual). Although a limited number
of studies have been performed on this topic, all three bioassays
described above seem to have large variability within and
between centers. These issues should be improved by test
standardization, which is a work in progress led by the
European ECFS Clinical Trials Network (CTN) and the
Therapeutics Development Network (TDN) of the US Cystic
Fibrosis Foundation (CFF) [4]. Reference parameters for nasal
and rectal transepithelial Cl− secretion and, more generally,
clinically relevant thresholds of response to CFTR bioactive
compounds need to be further investigated. Studies are lacking
in infants and preschool children because those tests are
difficult to perform (e.g. NPD or diagnostic thresholds have not
been established). Studies combining these three biomarkers
are required to gain more accuracy in CFTR expression pattern
according to the tissues and to implement the most sensitive
panel of biomarkers as clinical trial endpoints.
1.2. Innovative methods to assess CFTR function in sweat
glands by Tanja Gonska
Gonska pointed out that the current sweat Cl− test, based on
quantitative pilocarpine iontophoresis (QPIT) [11], still serves
as the gold standard test to confirm a clinical diagnosis of CF
[12]. Further, it is a very responsive biomarker to assess the
efficacy of novel CFTR targeting drugs [5]. Despite the goodperformance of this test, there are large overlaps of sweat Cl−
test results among healthy controls, obligate heterozygotes (i.e.,
parent of CF patients who carry just one CFTR mutation),
patients with a diagnosis of a CFTR-related disorder carrying 1
or 2 CFTR mutations associated with residual function, and
even some patients with a diagnosis of CF [13,14]. Further, based
solely onQPIT, patients carrying certain CFTRmutations such as
3849+10kbCNT or D1152H may not be identified as CF [15,16].
The lab of Paul Quinton and the Toronto group have
recently jointly developed two new methods to assess CFTR
function at different levels of the sweat gland: 1) the sweat
gland potential difference (SPD) assay which targets CFTR
function at the level of sweat duct capturing its absorptive
function; [17] and the β-adrenergic sweat secretion assay which
allows assessment of CFTR as secretory channel in the
secretory coil of the sweat gland [18].
Gonska explained these two methods in further detail. The
SPD can be measured between a topical and an intra-cutaneous
placed electrode following sweat stimulation using iontopho-
resis of a cholinergic, or cholinergic plus β-adrenergic agent(s).
Following iontophoresis application of water-saturated mineral
oil on the stimulated skin area is important to prevent current
shunts [17]. As published previously, the SPD was found to be
more negative in patients with CF compared to healthy controls
[19], due to loss of the Cl− diffusion potential across the CF
sweat duct [20]. Refinement of the measuring electrode as well
as development of an easier-to use software program has now
allowed the transfer of SPD into clinical studies. Direct
comparison of the SPD and QPIT in subjects with assumed
different CFTR functional levels such as healthy controls,
obligate heterozygotes, pancreatic sufficient (CF-PS) and
pancreatic insufficient CF (CF-PI) patients demonstrated
similar discriminatory abilities of both tests. Thus, while the
SPD offers an immediate read-out of the result, it does not add
functional information for a diagnosis of CF.
The second method Gonska presented was the β-adrenergic
sweat secretion test. Again, this test was based on an earlier
observation that sweat stimulation with β-adrenergic agents
induces small, but significant sweat secretion by the sweat
glands which was half maximal in heterozygotes and complete-
ly absent in CF patients [21,22]. The introduction of an
evaporimeter enabled capturing these low volume sweat
secretions and led to the development of a clinically applicable
sweat test protocol [18]. This protocol includes intracutaneous
injections of 1) a cholinergic agonist, 2) atropine to inhibit
cholinergic sweat secretion and 3) a cocktail of β-adrenergic
stimuli including isoproterenol, aminophylline and atropine and
measurement of the resulting sweat secretion. Under these
conditions, the resulting sweat secretion can be recorded by
placing the evaporimeter probe on the stimulated and treated
(water-saturated mineral oil) skin area. Direct comparison of
the β-adrenergic sweat secretory assay and the QPIT in subjects
presenting with assumed different CFTR functional levels such
as healthy controls, obligate heterozygotes, patients with a
CFTR-related disorder, CF-PS and CF-PI demonstrated
different discriminatory ability of both tests. As shown
earlier, the β-adrenergic sweat secretion was half-maximal in
366 J.M. Beekman et al. / Journal of Cystic Fibrosis 13 (2014) 363–372heterozygotes when compared to healthy controls and
completely absent in all CF patients including those with
3849+10kbCNT or D1152H and normal sweat Cl− results.
Clear discrimination among healthy controls, heterozygotes
and CF patients, supports this test as being the first functional in
vivo assay to identify carriers of one CFTR mutation. However,
the β-adrenergic sweat secretion assay was not able to
discriminate between CF-PS and CF-PI patients, whereas the
sweat Cl− test discriminated between the CF-PS and CF-PI
patients in the validation trial. Thus, the β-adrenergic sweat
secretion test, which offers immediate read-out results, adds
important functional information for a CF diagnosis. Respon-
siveness of both novel sweat tests to CFTR-targeted treatment
is currently investigated in ongoing studies.
2. Gut models
Three presentations focussed on the usage of intestinal
tissue from CF patients to assess CFTR function: Nico Derichs
and Marcus Mall who focussed on measurements of CFTR-
mediated Cl− secretion in native tissues (rectal biopsies) and
Jeffrey Beekman on intestinal organoids.
Originally, two distinct micro-Ussing chamber setups and
pharmacological activation protocols to analyze CFTR function
directly on native rectal tissues were developed. One setup
originally developed at the University Hospital Rotterdam uses
traditional re-circulating micro-Ussing chambers adapted to
accommodate small human rectal biopsies and a pharmacological
protocol that focussed primarily on Ca2+-mediated (i.e.
carbachol-induced) Cl− secretion as the primary outcome of
CFTR function in the rectal epithelium [23–27]. The other setup
was originally developed at the University of Freiburg and uses
continuously perfused micro-Ussing chambers to facilitate
studies of the effects of secretagogues and/or pharmacological
compounds on CFTR function under different experimental
conditions (e.g. in the absence and presence of endogenous
CFTR activation) in the same tissue in a strictly paired fashion.
The pharmacological protocol developed with this setup relies
primarily on cAMP-mediated Cl− secretion as an outcome of
CFTR function [8,28–32].Table 2
Summary of cAMP-induced bioelectric responses in rectal biopsies from non-CF sub
CF determined by perfused and recirculating Ussing chamber protocols. Assessme
circuit conditions and measurements in recirculating Ussing chambers under short c
Perfused Ussing chamber
(Isc-eq.-cAMP)
Recirculatin
(Isc-cAMP)
Multicenter trial SOP Original pro
Mean ± SEM Mean ± STD Mean ± SD
Non-CF 94.3 ± 8.6
(n = 19)
55.5 ± 11.1
(n = 26)
16.6 ± 14
(n = 28)
CF-PS 28.1 ± 2.9
(n = 18)
16.3 ± 2.8
(n = 12)
9.8 ± 6
(n = 7)
CF-PI −9.3 ± 1.7
(n = 27)
−11.3 ± 0.8
(n = 55)
1.9 ± 2
(n = 34)
Reference [9] [8] [10]
(n) indicates the number of individuals analyzed.From these, several independent protocols have been
developed more recently providing different measurements of
CFTR-mediated Cl− secretion with different sensitivities
(Table 2).
Comparison of these distinct approaches based on published
data, including a series of recent studies (see Table 2) indicates
that the perfused Ussing chamber setup with testing of
cAMP-mediated Cl− secretory responses as primary outcome
measure is more sensitive for quantitative assessment of
wild-type and mutant CFTR function. This leads to higher
discriminant power of CF patients, especially for those CF
patients with residual CFTR function when compared with
those without CFTR function. The evaluation of this pharma-
cological stimulation (with some variations) as a multicenter
standardized operating procedure (SOP) both within
ECFS-CTN and CFF-TDN using commercially available
recirculating Ussing chambers (to enhance standardization) is
currently ongoing. Hence, evidence from a series of indepen-
dent studies suggests that measurements of CFTR-mediated
Cl− secretion in rectal biopsies as a robust and reliable CFTR
biomarker that may be useful to assess response of mutant
CFTR to modulator therapy [8–10,23,24,29,33,34]. However,
it remains unknown whether the usage of commercial
equipment will be sensitive to detect residual function in
CF-PS (not assessed so far [35]), valuable for CF prognosis,
and modulation of mutant CFTR function.
A novel approach of intestinal organoids (also obtained from
the rectal biopsies) has been developed which not only allows
measurement of CFTR activity in biological samples of
unlimited growth potential but also seems to allow additional
unprecedented applications of the tissue, including its usage in
high-throughput screens for drug discovery (see below).
2.1. Rectal biopsies: intestinal current measurement (ICM) by
Nico Derichs
Nico Derichs introduced the topic of intestinal current
measurements (ICM) in rectal biopsies, by stating that it has
proven to be a sensitive CFTR biomarker for difficult CF
diagnoses and is a useful outcome measure to evaluate CFTRjects and pancreatic sufficient (PS) and pancreatic insufficient (PI) patients with
nt of CFTR function in perfused Ussing chambers was performed under open
ircuit conditions.
g Ussing chamber
tocol CFF TDN SOP ECFS CTN SOP
4.8 ± 4.0
(n = 16)
99.5 ± 71
(n = 17)
59.0 ± 24.9
(n = 37)
n.d. n.d. 25.9 ± 15.3
(n = 21)
0.2 ± 0.8
(n = 21)
−5.0 ± 12
(n = 44)
5.4 ± 16.7
(n = 40)
[41] [35] Preliminary data [37]
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equipment (e.g. perfused vs. recirculating Ussing chambers),
protocols (e.g. the order of CFTR stimulating agents) and
registration mode have complicated the comparison of results
and the establishment of center-independent diagnostic refer-
ence data [36]. First diagnostic reference data to sensitively
discriminate between CF-PI, CF-PS and non-CF had been
published for the ‘original’ recirculating protocol [10].
Consequently, the ECFS Diagnostic Network Working Group
and ECFS Clinical Trials Network worked to standardize ICM
across European sites (www.ecfs.eu/ecfs_dnwg). Based on
previous experience with both protocols, an SOP for ICM is
being developed and validated under the auspices of ECFS.
This includes a multicentre comparison for the definition of
diagnostic cut-offs for discrimination between residual CFTR
function in CF-PS and normal CFTR function in non-CF.
Preliminary data of this analysis have been presented at the
2013 North-American CF Conference [37]. Importantly, this
European SOP for ICM (under implementation in 10 European
sites) is being harmonized with the one by the TDN of the
Cystic Fibrosis Foundation in the US [35], to allow for
transatlantic multicentre trials on CFTR modulation in CF
patients with either severe and/or mild CFTR mutations.
Based on preliminary data, the ICM performed according to
the current European SOP for ICM seems to be highly
reproducible [38], sensitive to detect residual CFTR function
[37,38], and has excellent responsiveness to both ex vivo
incubation with CFTR correctors and in vivo oral ivacaftor
treatment [38,39], suggesting that this multicentre SOP may
have great value as CFTR biomarker in preclinical and clinical
studies.
Short- and long-term comparisons to other CFTR bio-
markers (sweat test, nasal potential difference) and clinical
surrogate parameters are underway and will help to define the
best strategy for designing next clinical trials of CFTR
modulators.
2.2. Assessment of CFTR function in rectal biopsies (perfused
chamber protocol) by Marcus Mall
Marcus Mall summarized the development and studies that
have been performed with the perfused micro-Ussing chamber
setups and discussed potential advantages as well as limitations
of this technique. The perfused Ussing chambers were
originally developed to study normal ion transport and CF
pathophysiology in the human colon. The use of continuous
perfusion approach has made it possible to study effects of
secretagogues under different experimental conditions (e.g. in
the absence and presence of cAMP-mediated stimulation)
within the same tissue. These studies demonstrated that CFTR
is essential for Cl− secretion in human colon and that
CFTR-mediated secretion relies on co-activation of cAMP-
and Ca2+-dependent K+ channels in the basolateral membrane
of the colonocyte that provide the driving force for luminal Cl−
exit through CFTR [28–30].
In patients with CF, assessment of CFTR function by
this protocol allows discrimination between two functionalphenotypes, a group with little or no detectable CFTR function
and a smaller group (~15–20%) with residual CFTR function
evidenced by an attenuated Cl− secretory response to
cAMP-dependent activation [8,9]. Further, two international
multicentre studies including patients with rare CFTR geno-
types and atypical CF phenotypes at study sites in Europe and
South America demonstrated that CFTR function determined
by this technique correlates with the CFTR genotype and CF
phenotype. CF patients lacking detectable CFTR function
typically carry two severe CFTR mutations (classes I to III) and
present with a classical CF phenotype with exocrine pancreatic
insufficiency (PI), whereas CF patients with residual function
carry at least one mild CFTR mutation (classes IV and V) and
present with a milder or atypical form of CF including
pancreatic sufficiency [8,9,40].
A recent proof-of-concept study using the first generation
potentiator 1-EBIO (1-ethyl-2-benzimidazolone), a K+ channel
opener demonstrated to potentiate CFTR-mediated Cl− secre-
tion, demonstrated that this ICM protocol is sensitive to detect
pharmacological potentiation of mutant CFTR function in
native rectal tissues from patients with a large spectrum of
CFTR genotypes [34]. These results suggest that ICM may be a
sensitive quantitative endpoint of CFTR function in studies
investigating the response of F508del-CFTR, but also rare
CFTR mutations to emerging CFTR modulators in individual
patients, and may thus guide the implementation of individu-
alized mutation-specific therapy for patients with CF.
Taken together, these studies suggest that this ICM protocol
provides a sensitive biomarker of CFTR function that can be
applied for diagnostic workup of patients with equivocal
diagnosis and characterization of CFTR mutations with
unknown functional consequences, and provide valuable
information. Compared to other ICM techniques (see
Table 2), the perfused Ussing chamber protocol detects
substantially higher cAMP-induced currents in non-CF rectal
tissues suggesting that it may also be more sensitive to quantify
residual CFTR function in CF (Table 2). This quality may be
critical when ICM is considered as a novel quantitative
endpoint in preclinical and early clinical testing of emerging
mutation-specific therapies for CF [8–10,41].
2.3. Intestinal organoids by Jeffrey Beekman
Recent advances in adult stem cell culture technology have
enabled the long-term expansion of human intestinal epithelial
tissue in vitro (reviewed in [42]). This technology was applied
to expand intestinal CF tissue using biopsies from ICM
measurements. Crypts are isolated from biopsies and are placed
in a 3D-culture environment containing essential growth factors
that maintain the “stemness” of the epithelial stem cell compart-
ment. The crypts rapidly close and grow into self-organizing
spheroid structures consisting of a single epithelial cell layer
and containing multiple crypts and villus-like domains
surrounding a central lumen. Forskolin-induced luminal fluid
secretion is completely CFTR dependent and can be accurately
quantified by measurement of organoid swelling using live cell
imaging [43].
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culturing intestinal organoids when compared with other existing
primary cell models for CF such as primary airway epithelial cell
cultures that require multiple culture conditions and transfer to
filters for terminal differentiation at the air–liquid interface.
Within weeks after culture, a large dataset can be generated in
which CFTR residual function and response to (combinations of)
CFTR modulators is able to be accurately measured for an
individual patient sample. Importantly, CFTR residual function
measurements in organoids can quantitatively reflect ICM
measurements in the biopsies from which the cultures were
derived [43]. After measurements of currently available CFTR
restoring drugs, cells can be biobanked for future analyses of new
therapeutic agents without requiring further sampling and patient
discomfort. This assay can thus play an important role in
prospectively defining optimal (combination of) treatments for
patients in a cost-effective and patient-specific manner.
Intestinal organoids can also play an important role at the
preclinical phase of CFTR modulator development [44]. The ease
of culture, and straightforward and robust CFTR function
measurement would allow rapid development of high-throughput
drug discovery approaches for CF in a primary cell model for the
first time. In collaborations with Dr. Lukacs and Dr. Bear, the
intestinal organoid model has been shown to be suitable for
identification of compounds that synergize with VX-809 in
correcting CFTR-F508del, and showed similar results for
interactions between CFTR modulators and isolated CFTR in
proteoliposomes [45,46].
Finally, novel advances in gene editing of adult stem cells may
offer the development of novel disease models and regenerative
medicine approaches for CF. Schwank et al. recently published
the functional repair of CFTR by CRISPR/Cas9 technology in
intestinal organoids [47]. This proof-of-concept study has
indicated that CFTR gene corrected clonal intestinal stem cells
can be selected and characterized in vitro. This remains a highly
experimental approach, yet may lead to future therapies in which
the patient's own stem cells are genetically repaired in vitro and
used to replace resident tissue stem cells for the regeneration of
disease-free tissue in affected organs. For now, this approach is
ideal to generate novel disease models and reporter cells for drug
discovery and scientific studies.
3. Airway models
Four presentations focussed on the use of airway cells from
CF patients to assess CFTR function, drug discovery and
potentially other applications: Anil Mehta, Margarida Amaral
and Mitch Drumm who focussed on primary cultures of lower
and upper respiratory tract airway cells and Ulrich Martin on
stem cells.
Indeed, despite the acceptance of rectal tissue in diagnosis
and prognosis [39], it still involves some degree of invasiveness
and requires an experienced gastroenterologist/ endoscopist
who is not always available at all CF centers. Moreover, it is
often claimed that CFTR function would be most appropriately
determined in the airways, as the major focus of CF morbidity
and mortality.Monolayers of primary human bronchial epithelial (HBE)
cells have thus been used in many studies as the gold standard
for validation of both mechanisms of CF disease and for
pre-clinical validation of CFTR modulator therapies.
Despite their outstanding value, primary HBE cells are
scarce, difficult to obtain and not easily grown at every
point-of-CF care. These reasons prevent its more widespread
use in CF diagnosis, in determining prognosis and in assessing
response to therapy in a prospective manner. Growth limita-
tions also limit the application of HBE cells in drug discovery
programs.
However, innovative approaches are emerging which seem to
allow the usage of nasal cells for more widespread use. Similarly,
new possibilities are arising from increasing knowledge on how
to generate induced pluripotent stem cells (iPSCs), which grow
indefinitely and thus have potential for use in high-throughput
drug screening projects. These recent advances help moving the
CF field forward at a much faster pace.
3.1. Nasal cells by Anil Mehta
The airway epithelium lining the inferior turbinate bones of
the nose, when cultured ex vivo at an air liquid interface (ALI)
culture recapitulates many of the ion transport characteristics of
the airways of the lung [48]. Because of the relative ease of
access and the minimal discomfort during nasal scrapings or
brushings, this multicellular epithelial source has become the de
facto “standard” for many groups. However, many different
(and often unclear) protocols are used to culture cells that may
impact ion transport characteristics and response to modulators
which limits uniformity in data generated between different
centers [49].
For example, two recently published methods provide a
compendium of the applied protocols that underscore two
different approaches: the use of serum-free culture media with
the addition of synthetic hormones and growth factors [50] or
the use of media supplemented with Ultroser G serum
substitute [51]. In addition, a debate is still ongoing regarding
the levels of transepithelial resistance (TER) that airway (and in
particular nasal) cells have to achieve in culture and the
meaning of the observed values of current when compared to
data obtained from analysis of isolated biopsies of airway
mucosa [52]. Despite the presence in the literature of reports
attesting the effects of different concentrations of hormones and
growth factors for the culture of airway cells, at present an
agreement on cell culture conditions as one or more SOPs has
not been established yet [49].
One of the objectives of the recently created ECFS Working
Group on Basic Science of CF is to standardize all of the above.
An equally important goal is the interpretation of the resultant
ion transport characteristics that is currently hampered by the
paucity of normal ranges from healthy subjects. The absence of
such apparently simple baseline data hinders the work of newly
entrant research groups and biotechnology companies to the
field. The overall goal of all the protocols published is to
demonstrate the efficacy of the different methods to expand
and differentiate isolated cells into fully polarized ciliated
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(albeit variable numbers of) basal, goblet and ciliated cells, with
a measurable TER and demonstrable vectorial ion transport.
Ultimately, these in vitro cultures should recapitulate the
clinical in vivo situation as accurately as possible, and hence,
protocols that most robustly correlate with clinical observations
are required.
3.2. Primary cultures of lung and nasal cells by
Margarida Amaral
Until recently, although useful for many studies [53–59],
nasal cells freshly obtained from CF patients could not be used
in Ussing chamber for bioelectric measurements because of the
relatively low number of cells obtained by this approach
(typically 1–2 × 106 cells) and limited ability to promote
expansion through culturing as primary cultures because of the
high cell mortality after a few passages. Notwithstanding, usage
of these cells in electrophysiological measurements has been
demonstrated previously, albeit through patch-clamping which
is a difficult to standardize technique [60].
However, in a recent real breakthrough in epithelial biology,
Schlegel et al. reported that normal adult epithelial cells can be
induced to a “stem-like” state in which they proliferate indefinitely
in vitro, through a Rho kinase inhibitor (Y-27632) in combination
with fibroblast feeder cells [61,62].
Data were presented confirming these findings applied to
nasal epithelial cells obtained by brushing as previously
described [57]. Very promisingly, preliminary data indicate
that monolayers of these cells can be assessed in perfused
Ussing chambers for CFTR-mediated Cl− secretion, similarly
to rectal biopsies (see above) or primary cultures of lung cells.
Further work is ongoing to validate this in vitro approach,
which integrates the individual's combination of CFTR
mutations plus other favorable or unfavorable variants of
modifier genes, for its use in CF diagnosis, disease prognosis
and for predicting in vivo drug efficacy.
3.3. Induced pluripotent stem cells by Ulrich Martin
Induced pluripotent stem cells (iPSCs) represent another
patient / disease-specific cell source for disease modeling and
drug screening [63]. Similar to embryonic stem cells, these cells
show an unlimited potential for proliferation and differentiation
and they can now be readily generated from various somatic cell
types including easily accessible sources such as blood [64].
Recent critical advances in the field include scalable mass
production [65] and targeted differentiation of such cells [66],
indicating that technologies exists for large-scale production of
patient and mutation-specific cell lineages. Importantly, with
patient-specific iPSCs a “universal cell type” will be available
and thus provide the basis for different disease-relevant
organotypic in vitro models including lung, bile duct and
intestine.
Moreover, the development of novel highly efficient
genome engineering approaches, including the CRISPR/Cas9
system and TALE Nucleases (TALENS) [67], allows thegeneration of CFTR gene-corrected human cells as crucial
isogenic controls for studying the effects of a specific CFTR
mutation in a given genetic background. Likewise, CFTR
mutations of choice can be introduced and studied, e.g. in case
of rare mutations for which no homozygous patient is available.
Furthermore, iPSC reporter lines with constitutive expression
of halide- or voltage-sensitive fluorescent proteins for func-
tional drug screens or molecularly tagged endogenous CFTR
allowing for direct visualization of trafficking can be generated
for drug screening purposes.
Although iPSCs can already be differentiated into CF
relevant cell types such as respiratory derivatives [68] and bile
duct epithelium [69], existing complex and cost-intensive
differentiation protocols definitely represent the major bottle-
neck for utilization of iPSCs in CF disease modeling and drug
screening. With the likely development of improved culture
techniques during the next few years, genetically engineered
patient-specific iPSC derivatives will provide a basis not
only for a better understanding of the different CF disease
phenotypes but also for identification of further clinically
applicable drugs that are able to functionally correct the
organ-specific consequences of the different classes of CFTR
mutations.
3.4. Modification of human respiratory cells by Mitch Drumm
The ability to expand primary airway epithelial cells
provides immense potential for both mechanistic studies as
well as a resource for drug screening. However, the limitations
of cells expanded through this method are currently not fully
understood. One use of the cells is the creation of matched,
isogenic cells in which the only genetic difference is the CFTR
genotype. To create such cells, gene editing procedures are
being explored, such as zinc-finger nucleases and the
CRISPR/Cas9 system. Although these procedures are effi-
cient, there is significant variation among cells exposed to the
procedure as some cells will be heterozygous for an intended
mutation, some homozygous and some not mutated at all.
Thus, selection and growth of clonal cells with identical
gene-editing events are necessary to achieve pure populations
for optimal analysis. Data from Mitchell Drumm (and also
generated by Calvin Cotton at Case Western Reserve
University) demonstrated that single-cell clones in which the
CFTR gene had been inactivated by CRISPR/Cas9-mediated
mutagenesis could be created and expanded. To select potential
gene-edited cells, cells were transfected by CRISPR guide RNA
recognizing CFTR and a Cas9-expressing plasmid also express-
ing GFP. This allowed efficient sorting of GFP expressing cells
using fluorescence-activated cell sorting. Cells were subsequent-
ly seeded on irradiated 3T3 fibroblast feeder layers and expanded.
Clones were subsequently moved to transwell filters for
polarization and those cells are currently being analyzed for
their ability to differentiate at air–liquid interface (ALI) culture
conditions and their electrophysiological and gene expression
properties. These preliminary studies indicate the primary cells
can be genetically manipulated and that clonal selection is
possible.
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Clear progress has been made over the recent years in
developing standardized objective readouts for individual CFTR
residual function and the use of such measurements for CF
diagnosis, defining disease severity (prognosis) and the in vivo
efficacy of CFTR modulating therapy. Many of the different
techniques show distinct dynamic ranges for the measurement of
CFTR function, indicating that these multiple approaches are
required to differentiate between distinct levels of CFTR function
that are associated with severe and milder forms of CFTR-related
diseases and the various CFTR-targeting therapies.
In addition, novel advances in stem cell culture technology
indicate that in vitro cultures of patients can play a role in
measuring CFTR residual function and prospectively defining
the optimal (combination of) therapy for each individual with
CF. These models will also allow for the development of more
effective drug screening platforms. Emphasis is required on
using tissues and culture protocols that combine accurate
prediction of clinical disease characteristics with as limited
patient discomfort as possible.
For both the in vivo and in vitro biomarkers, reference
values and thresholds for CF diagnosis, correlation to disease
severity and significant responses to therapy need to be further
established. European research efforts should be coordinated to
speed up the promising developments presented at this
conference and to jointly potentiate the efforts of the National
Patient Associations.
A Working Group on Basic Science of CF has recently been
created at ECFS in order to complement the already established
European ECFS Clinical Trials Network and the ECFS
Diagnostic Network Working Group. The aim is to i) further
standardize human in vitro models across various European CF
research centers to help defining correlations between CFTR
genotypes, CFTR function, and CF phenotypes along with
response to CFTR-modulating therapies for the individual
patient, and to ii) further standardize the platforms for research
and preclinical drug development across various locations so
that they can be used as bona fide CF disease biomarkers.
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